JAMES WALLA: Open Payments
NPI 1689288615 · ANN ARBOR, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,422 in 74 payments from 13 companies in 2025. Trend: 2023 $45 · 2024 $750 · 2025 $1,422
Food & beverage: $1,422
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $311 |
| Lundbeck LLC | 13 | $246 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $218 |
| Vanda Pharmaceuticals Inc. | 10 | $173 |
| Otsuka America Pharmaceutical, Inc. | 11 | $154 |
| Alkermes, Inc. | 3 | $79 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| ABBVIE INC. | 2 | $37 |
Products named: REXULTI, INGREZZA, CAPLYTA, HETLIOZ, ARISTADA, Jornay PM, ABILIFY MAINTENA, Qelbree.
Industry payments across MI — which companies pay providers there.
